William E. Cohn - Apr 27, 2023 Form 4 Insider Report for Cardiovascular Systems Inc (CSII)

Role
Director
Signature
/s/ Andrew Nick as Attorney-in-Fact for William E. Cohn pursuant to Power of Attorney previously filed.
Stock symbol
CSII
Transactions as of
Apr 27, 2023
Transactions value $
-$188,980
Form type
4
Date filed
4/27/2023, 04:33 PM
Previous filing
Aug 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CSII Common Stock Disposed to Issuer -$189K -9.45K -100% $20.00 0 Apr 27, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CSII Restricted Stock Units Disposed to Issuer $0 -40.6K -100% $0.00* 0 Apr 27, 2023 Common Stock 40.6K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

William E. Cohn is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger by and among Cardiovascular Systems, Inc., a Delaware corporation, Abbott Laboratories, an Illinois corporation, and Cobra Acquisition Co., a Delaware corporation (the "Merger Agreement"), each share of common stock converted pursuant to the Merger Agreement into the right to receive $20.00 in cash per share, without interest and less any required withholding taxes.
F2 Pursuant to the Merger Agreement, each unvested restricted stock unit became fully vested immediately prior to the effective time of the merger. Restricted stock units were then cancelled as of the effective time of the merger in exchange for the right to receive a cash payment equal to $20.00 multiplied by the number of restricted stock units, without interest and less any required withholding of taxes.